文献速递妇科

低剂量艾拉戈利治疗子宫平滑肌瘤所致月经过多的随机对照试验

Low-Dose Elagolix for the Treatment of Heavy Menstrual Bleeding in Patients With Uterine Leiomyomas: A Randomized Controlled Trial.
PubMed 文献 · Obstet Gynecol · 2023-09-28

这项4期随机双盲安慰剂对照研究纳入82例子宫平滑肌瘤相关月经过多的绝经前患者,按2:1随机接受艾拉戈利150 mg每日一次或安慰剂治疗6个月。艾拉戈利组49.4%达到主要终点,安慰剂组23.3%(P=.035),艾拉戈利总体耐受良好,未报告严重或重度不良事件。

要点

  • 艾拉戈利150 mg每日一次组49.4%达到主要终点,安慰剂组23.3%(P=.035)。
  • 艾拉戈利组月经失血量较基线的平均减少在第1个月即出现统计学显著差异(第1-3个月和第5个月P<.05)。
  • 艾拉戈利组未报告严重或重度不良事件,安慰剂组7.1%发生严重不良事件。

核心结论

  • 在绝经前子宫平滑肌瘤相关月经过多患者中,艾拉戈利150 mg每日一次单药治疗较安慰剂显著改善月经过多。
  • 艾拉戈利150 mg每日一次在本研究中总体耐受良好,未出现新的安全性信号。

研究设计与样本

  • 4期、随机、双盲、安慰剂对照、为期6个月的治疗研究。
  • 纳入18-51岁绝经前患者,月经过多定义为一个月经周期内月经失血量大于80 mL,且与子宫平滑肌瘤相关。
  • 患者按2:1随机接受艾拉戈利150 mg每日一次或安慰剂。
  • 共82例随机化患者,艾拉戈利150 mg组54例,安慰剂组28例。
  • 主要终点为最后一个月月经失血量降至小于80 mL且从基线至最后一个月月经失血量减少至少50%。

主要发现

  • 艾拉戈利组49.4%(95%CI 35.1-63.8%)达到主要终点,安慰剂组23.3%(95%CI 7.2-39.5%),P=.035。
  • 艾拉戈利组与安慰剂组月经失血量较基线的平均减少在第1个月即出现统计学显著差异(第1-3个月和第5个月P<.05)。
  • 接受艾拉戈利治疗的患者中出血抑制比例显著高于安慰剂组(P=.036)。
  • 艾拉戈利组在闭经患者比例、血红蛋白浓度和健康相关生活质量方面的改善优于安慰剂组。
  • 艾拉戈利组未报告严重或重度不良事件;安慰剂组7.1%的参与者发生严重不良事件(新型冠状病毒感染 n=1,悬雍垂肿大 n=1)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the safety and efficacy of elagolix 150 mg once-daily monotherapy in patients with heavy menstrual bleeding associated with uterine leiomyomas. METHODS: A phase 4, randomized, double-blind, placebo-controlled, 6-month treatment study was conducted in premenopausal patients aged 18-51 years with heavy menstrual bleeding (defined as menstrual blood loss greater than 80 mL during one menstrual cycle) associated with uterine leiomyomas. Patients were randomized 2:1 to receive elagolix 150 mg once daily or placebo. The primary endpoint was reduction in menstrual blood loss volume to less than 80 mL at the final month and at least a 50% reduction in menstrual blood loss volume from baseline to the final month. RESULTS: Of 82 randomized patients, 54 received elagolix 150 mg and 28 received placebo. With elagolix, 49.4% (95% CI 35.1-63.8%) of patients met the primary endpoint, compared with 23.3% (95% CI 7.2-39.5%) of patients who received placebo ( P =.035). Statistically significant differences between elagolix and placebo in mean reduction of menstrual blood loss from baseline were seen as early as month 1 ( P <.05 for months 1-3 and 5). Significantly more patients receiving elagolix experienced suppression of bleeding compared with placebo ( P =.036). Greater improvements were observed in the elagolix group (vs placebo) in the proportion of patients with amenorrhea, in hemoglobin concentrations, and in health-related quality of life. No serious or severe adverse events were reported for elagolix, compared with 7.1% of participants in the placebo group having serious adverse events (coronavirus disease 2019 [COVID-19] n=1, enlarged uvula n=1). Three patients (5.6%) discontinued elagolix due to adverse events. CONCLUSION: Elagolix 150 mg once-daily monotherapy significantly improved heavy menstrual bleeding associated with uterine leiomyomas compared with placebo in premenopausal patients. Treatment with elagolix 150 mg once daily was generally well-tolerated in this study, with no new safety signals. FUNDING SOURCE: AbbVie Inc. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT03886220.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Brown E, Kroll R, Li H, et al. Low-Dose Elagolix for the Treatment of Heavy Menstrual Bleeding in Patients With Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2023. PMID: 37769311. doi:10.1097/AOG.0000000000005380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。